The genetic determinants of the CYP3A5 polymorphism.

By E. Hustert, M. Haberl, O. Burk, Renzo Wolbold, Y. He, K. Klein, Andreas Nuessler, P. Neuhaus, J. Klattig, R. Eiselt and 6 more. Pharmacogenetics (London), 2001

714 citations recorded by the source corpus.

Subfields: Oncology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/f8a75c31c4be20a0f47885cb7b4230bb2134a869

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pharmacology

Citations in the corpus

Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “The vitamin D receptor (VDR), another transcriptional regulator of CYP3A4, is also regulated by the CYP3A4-targeting miR-27b, resulting in an indirect and a direct mechanism for miRNA regulation of CYP3A4 (Pan et al., 2009).”
Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, neutral): “…−3557T>C; −1617T>C; −795T>A; 173_175delGGA; 5215C>T; 7182C>A; 7424_7427insCTAAAAAAT; 13077T>G; 13173T>C; 16931_16932insGTC; 17163G>T; 19165G>A; 27526C>T (Hustert et al., 2001) – 7303C>A S100Y (Hustert et al., 2001) – 16025A>G; 16993C>G; 27448C>A (Saeki et al., 2003) – −15A>C; 3818G>A; 13134C>G;…”
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus (2003, neutral): “5 (40-370) 210 (90-380) 12 mo 145 (80-430) 140 (20-320) 125 (75-290) Cyclosporine C0/dose (ng/mL per mg/kg) 3 mo 45.”
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, background): “In this respect, CYP3A5 is a highly polymorphic enzyme as a consequence of mutations that severely diminish the synthesis of functional CYP3A5 protein (CYP3A5⁎3, ⁎6 and ⁎7; Hustert et al., 2001; Kuehl et al., 2001).”